Freshfields advises Grünenthal on its acquisition of Valinor Pharma

Freshfields Bruckhaus Deringer (“Freshfields”) advised international pharmaceutical company Grünenthal on its acquisition of Valinor Pharma and its product Movantik^® (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. The transaction further expands Grünenthal's portfolio of established medicines and adds to the company's growing U.S. business.

Read more about this transaction here.

Freshfields worked closely with Grünenthal's global in-house team led by Sebastian Köhler (General Counsel), Benjamin Kaiser (Senior Legal Counsel & Head of Legal M&A) and Megan Renze (Senior Legal Counsel; Global Projects & Head of Legal LatAm).

The Freshfields team comprised

• Corporate/M&A and Life Sciences Transactions: Partners Adam H. Golden (New York), Kristen Riemenschneider (D.C.) and Oliver J. Board (New York), Associates Ryan Taylor, Jake Silvers, Chinyere Obi, Nana Kessie, Laura Zhu and Tanny Kang (all New York)

• Executive Compensation and Benefits: Partner Nicole Foster, Senior Associate Jeffrey Anand, Associate Jordan Riley (all New York)

• Tax: Partner Joe Soltis (New York), Senior Associate Brendan Counihan (D.C.)

• Real Estate: Counsel Jeremiah Nelson (Silicon Valley), Associate Casey Hagen (New York)

• Finance: Partner Kyle Lakin (New York), Senior Associate Sonam Cheema (London)

• IP: Partner Mena Kaplan (New York), Senior Associate Daniel Spencer (D.C.)

• Antitrust, Competition and Trade: Partners Meghan Rissmiller (D.C.) and Rod Carlton (London), Special Counsel Charles Ramsey (D.C.), Associate Katie Kissinger (New York)